Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/134750
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | NADPH oxidases as therapeutic targets in chronic myelogenous leukemia |
Autor: | Gutiérrez-Herrero, Sara; Pandiella, Atanasio CSIC ORCID CVN ; Guerrero Arroyo, María del Carmen CSIC ORCID ; San Miguel, Jesús F. CSIC ORCID; Sánchez-Guijo, Fermín M. CSIC ORCID; Cañizo, María Consuelo del; Hernández-Hernández, Ángel CSIC ORCID | Fecha de publicación: | 2014 | Editor: | American Association for Cancer Research | Citación: | Clinical Cancer Research 20(15): 4014-4025 (2014) | Resumen: | [Purpose]: Cancer cells show higher levels of reactive oxygen species (ROS) than normal cells and increasing intracellular ROS levels are becoming a recognized strategy against tumor cells. Thus, diminishing ROS levels could be also detrimental to cancer cells. We surmise that avoiding ROS generation would be a better option than quenching ROS with antioxidants. Chronic myelogenous leukemia (CML) is triggered by the expression of BCR-ABL kinase, whose activity leads to increased ROS production, partly through NADPH oxidases. Here, we assessed NADPH oxidases as therapeutic targets in CML. [Experimental Design]: We have analyzed the effect of different NADPH oxidase inhibitors, either alone or in combination with BCR-ABL inhibitors, in CML cells and in two different animal models for CML. [Results]: NADPH oxidase inhibition dramatically impaired the proliferation and viability of BCR-ABL-expressing cells due to the attenuation of BCR-ABL signaling and a pronounced cell-cycle arrest. Moreover, the combination of NADPH oxidase inhibitors with BCR-ABL inhibitors was highly synergistic. Two different animal models underscore the effectiveness of NADPH oxidase inhibitors and their combination with BCR-ABL inhibitors for CML targeting in vivo. [Conclusion]: Our results offer further therapeutic opportunities for CML, by targeting NADPH oxidases. In the future, it would be worthwhile conducting further experiments to ascertain the feasibility of translating such therapies to clinical practice. | URI: | http://hdl.handle.net/10261/134750 | DOI: | 10.1158/1078-0432.CCR-13-3044 | Identificadores: | doi: 10.1158/1078-0432.CCR-13-3044 e-issn: 1557-3265 issn: 1078-0432 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
37
checked on 12-abr-2024
WEB OF SCIENCETM
Citations
35
checked on 17-feb-2024
Page view(s)
230
checked on 18-abr-2024
Download(s)
80
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.